Edwards Lifesciences Corporation (EW)

Healthcare • Medical Devices

StockNYSEUnited StatesUS28176E1082

105.86 USD +0.05% today Updated 12 Nov 2026 21:11

Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Edwards Lifesciences Corporation, and has no access to any account you may have with it. The name and the logo belong to their owners.

Price history

Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.

All time

Updated 12 Nov 2026 21:11. Information, not advice. Showing the last 12 months. Create a free account to see the whole history

Results

Next results 09 Feb 2027 in 88 days · 16:00 · estimate 0.66

Last results 0.80 vs 0.74 estimated 04 Nov 2026 · Beat +8.6%

Beat the estimate 9 of 12 1 missed · 2 in line · 3 beats in a row

Average surprise +5.6% reported against the estimate, last 12 quarters

Earnings per share: estimate and reported

Estimate Reported: beat Reported: miss In line

Quarterly results

Date	EPS estimate	EPS reported	Surprise	Result
09 Feb 2027 16:00	0.66	—	—	Upcoming
04 Nov 2026 16:00	0.74	0.80	+8.6%	Beat
23 Jul 2026 16:00	0.74	0.78	+5.3%	Beat
23 Apr 2026 16:00	0.73	0.78	+7.3%	Beat
10 Feb 2026 16:00	0.62	0.58	-6.3%	Miss
30 Oct 2025 16:00	0.59	0.67	+12.6%	Beat
24 Jul 2025 16:00	0.62	0.67	+7.6%	Beat
23 Apr 2025 16:00	0.60	0.64	+7.5%	Beat
11 Feb 2025 16:00	0.55	0.59	+6.4%	Beat
24 Oct 2024 16:00	0.59	0.67	+14.0%	Beat
24 Jul 2024 16:00	0.69	0.70	+0.9%	In line
25 Apr 2024 16:00	0.64	0.66	+2.8%	Beat
06 Feb 2024 16:00	0.64	0.64	+0.2%	In line
25 Oct 2023 16:00	0.59	0.59	-0.7%	In line
26 Jul 2023 16:00	0.65	0.66	+1.9%	Beat
26 Apr 2023 16:00	0.61	0.62	+2.0%	Beat
31 Jan 2023 16:00	0.61	0.64	+4.5%	Beat
27 Oct 2022 16:00	0.62	0.61	-2.0%	Miss
28 Jul 2022 16:00	0.64	0.63	-1.4%	Miss
26 Apr 2022 16:00	0.57	0.60	+5.2%	Beat
26 Jan 2022 16:00	0.55	0.51	-6.8%	Miss
27 Oct 2021 16:00	0.53	0.54	+1.7%	Beat
29 Jul 2021 16:00	0.55	0.64	+15.6%	Beat
20 Apr 2021 16:00	0.47	0.54	+13.9%	Beat
27 Jan 2021 16:00	0.53	0.50	-5.5%	Miss
21 Oct 2020 16:00	0.44	0.51	+15.1%	Beat
23 Jul 2020 16:00	0.19	0.34	+82.3%	Beat
23 Apr 2020 17:00	0.41	0.50	+23.3%	Beat
30 Jan 2020 16:00	0.50	0.49	-1.7%	Miss
23 Oct 2019 16:00	0.41	0.47	+15.8%	Beat
23 Jul 2019 16:00	0.44	0.46	+3.9%	Beat
23 Apr 2019 16:00	0.41	0.44	+7.9%	Beat
31 Jan 2019 16:00	0.39	0.39	0.0%	In line
23 Oct 2018 16:00	0.34	0.36	+5.3%	Beat
26 Jul 2018 16:00	0.38	0.41	+9.5%	Beat
24 Apr 2018 16:00	0.37	0.41	+9.6%	Beat
01 Feb 2018 16:00	0.30	0.31	+3.4%	Beat
24 Oct 2017 16:00	0.29	0.28	-2.5%	Miss
26 Jul 2017 16:00	0.29	0.36	+22.6%	Beat
25 Apr 2017 16:00	0.27	0.31	+14.3%	Beat
01 Feb 2017 16:00	0.24	0.25	+4.7%	Beat
25 Oct 2016 16:00	0.23	0.23	+0.4%	In line
26 Jul 2016 16:00	0.23	0.25	+8.5%	Beat
26 Apr 2016 16:00	0.22	0.24	+8.0%	Beat
02 Feb 2016 16:00	0.20	0.21	+5.6%	Beat
26 Oct 2015 16:00	0.16	0.18	+9.3%	Beat
28 Jul 2015 16:00	0.17	0.19	+7.7%	Beat
23 Apr 2015 16:00	0.17	0.19	+7.3%	Beat
03 Feb 2015 16:00	0.16	0.18	+12.0%	Beat
23 Oct 2014 16:00	0.12	0.13	+11.5%	Beat

Annual results · USD

Year	Revenue	Change	Net income	Net margin	EPS	EPS change	Free cash flow
2025	6.1B	+11.5%	1.1B	17.7%	1.83	-73.7%	1.3B
2024	5.4B	+8.6%	4.2B	76.7%	6.97	+203.0%	259.9M
2023	5B	+12.2%	1.4B	28.0%	2.30	-5.7%	629.5M
2022	4.5B	—	1.5B	34.1%	2.44	—	953.4M

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Day Week Month

Price history in USD, by month
Period	Opening price	High	Low	Closing price	Change	Volume
Nov 2026 In progress	93.16	106.77	87.90	105.86	+15.05%	59,145,262
Oct 2026	85.99	95.34	82.43	92.01	+6.59%	78,606,300
Sep 2026	91.39	92.95	83.81	86.32	-4.88%	71,430,700
Aug 2026	86.89	93.91	86.39	90.75	+5.44%	63,545,200
Jul 2026	91.01	96.29	81.16	86.07	-4.85%	113,424,700
Jun 2026	86.55	92.88	83.17	90.46	+4.61%	108,497,800
May 2026	84.01	88.28	76.49	86.47	+3.56%	96,399,500
Apr 2026	81.00	84.95	77.10	83.50	+4.27%	117,221,100
Mar 2026	85.67	87.32	77.60	80.08	-7.39%	103,383,200
Feb 2026	81.44	86.95	74.66	86.47	+6.28%	103,411,900
00 Mon 0000	157.29	236.48	315.67	394.86	+0.00%	000,000
00 Mon 0000	553.24	632.43	711.62	790.81	+0.00%	000,000
00 Mon 0000	49.19	128.38	207.57	286.76	+0.00%	000,000
51 older periods: create a free account to see the whole history

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

News

TD Cowen Maintains Buy on Edwards Lifesciences, Raises Price Target to $121 (opens in a new tab) Benzinga · 11 Nov 2026 12:42
Edwards Lifesciences Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 07 Nov 2026 09:18
Edwards Life (EW) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 21:59
UBS Maintains Buy on Edwards Lifesciences, Raises Price Target to $118 (opens in a new tab) Benzinga · 05 Nov 2026 20:06
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120 (opens in a new tab) Benzinga · 05 Nov 2026 19:08
CAH Shares Post New Record, EW Stock Hits Over Three-Year High – What’s Driving Today’s Rally? (opens in a new tab) Stocktwits · 05 Nov 2026 18:07
Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $117 (opens in a new tab) Benzinga · 05 Nov 2026 17:38
Edwards Lifesciences Corp (EW) (Q3 2026) Earnings Call Highlights: Broad-Based TAVR and TMTT ... (opens in a new tab) GuruFocus.com · 05 Nov 2026 17:07
Edwards bumps up sales forecast on TAVR strength in Q3 (opens in a new tab) MedTech Dive · 05 Nov 2026 16:02
Leerink Partners Maintains Outperform on Edwards Lifesciences, Raises Price Target to $112 (opens in a new tab) Benzinga · 05 Nov 2026 15:50
RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $115 (opens in a new tab) Benzinga · 05 Nov 2026 15:03
Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120 (opens in a new tab) Benzinga · 05 Nov 2026 14:44
Bernstein Maintains Market Perform on Edwards Lifesciences, Raises Price Target to $106 (opens in a new tab) Benzinga · 05 Nov 2026 13:15
Edwards Lifesciences (EW) Trial Data Points To Earlier TAVR Use In Moderate Aortic Stenosis (opens in a new tab) Simply Wall St. · 05 Nov 2026 13:13
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $115 (opens in a new tab) Benzinga · 05 Nov 2026 12:55

Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.

Key data

Previous close: 105.81 USD
Market cap: 60.9B
Exchange: NYSE
Country: United States
Sector: Healthcare
Industry: Medical Devices
Currency: USD

Dividends

No dividends on record.

Why this score

How the score is made up
Part of the score	Points	Why
Business growth Yearly growth of revenue and of earnings per share.	9.0 / 25	Revenue growth of 10.8% a year Earnings per share growth of -9.1% a year
Quality Return on equity, net margin and how stable the margins are.	10.7 / 25	ROE of 9%
Financial strength Net debt against operating earnings, interest cover and free cash flow.	18.8 / 20	Net debt is -1.9× EBITDA Free cash flow yield of 1.9%
Valuation Free cash flow yield and the P/E against its sector.	2.4 / 15	P/E 60.5 against 30.6 for its sector
Analysts How far the analysts' average target is from today's price.	5.2 / 10	Analysts' target is +5% from the price

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works

Figures

Valuation
Figure	Value	Reading	Sector median
P/E (trailing)	60.47×	Weak	30.56×
P/E (forward)	30.57×	Weak	14.16×
Price / book	5.51×	Weak	3.5×
Price / sales	8.96×	Weak	3.33×
EV / EBITDA	26.72×	Weak	11.19×
Free cash flow yield	1.9%	Weak	2.1%

Quality
Figure	Value	Reading	Sector median
Gross margin	78%	Good	54.9%
Operating margin	30.2%	Good	5.8%
Net margin	15.3%	Good	1.2%
Return on equity	9.3%	Fair	4.4%
Return on assets	8.8%	Good	2.7%

Growth
Figure	Value	Reading	Sector median
Revenue growth / year	10.8%	Good	10.1%
EPS growth / year	-9.1%	Weak	10.2%

Financial health
Figure	Value	Reading	Sector median
Debt / equity	0.06×	Good	0.4×
Net debt / EBITDA	-1.88×	Good	1.46×
Interest cover	80.21×	Good	2.17×
Current ratio	4.6×	Good	2.64×

Dividends
Figure	Value	Reading	Sector median
Payout of earnings	0%	Weak	0%

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Similar shares

Follow EW and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in